Published in Cancer Res on September 15, 2008
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med (2014) 1.04
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One (2013) 1.04
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol (2013) 0.89
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunol Immunother (2011) 0.82
Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy (2009) 0.81
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology (2015) 0.78
Control of the adaptive immune response by tumor vasculature. Front Oncol (2014) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy. Korean J Physiol Pharmacol (2016) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer (2005) 3.31
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol (2003) 2.81
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res (2003) 2.50
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer (1998) 2.29
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol (2002) 2.05
The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int (2007) 1.82
Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis (1986) 1.59
ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood (1995) 1.33
Cancer therapy and renal injury. J Clin Invest (2002) 1.14
Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother (2001) 1.10
Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res (2001) 1.09
Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res (2007) 1.08
Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes. Immunology (2002) 0.85
4-1BB-like molecule is expressed in islet-infiltrating mononuclear cells and in the gray matter of the brain. Cell Biol Int (2002) 0.82
Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. Br J Cancer (1993) 0.82
4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes. Cell Immunol (2003) 0.81
4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med (2004) 3.01
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol (2002) 2.05
Immune responses in 4-1BB (CD137)-deficient mice. J Immunol (2002) 1.74
Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat Immunol (2007) 1.57
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol (2003) 1.54
Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol (2008) 1.42
Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine (2005) 1.40
Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol (2005) 1.38
TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J (2004) 1.33
CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation (2010) 1.26
CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol (2004) 1.22
Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol (2006) 1.21
Immunotherapy of cancer with 4-1BB. Mol Cancer Ther (2012) 1.19
Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest (2007) 1.17
Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood (2005) 1.14
Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood (2004) 1.13
4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine (2006) 1.13
Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med (Berl) (2006) 1.09
4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J Immunol (2008) 1.08
Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res (2007) 1.08
4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur J Immunol (2003) 1.06
Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J Immunol (2003) 1.05
4-1BB functions as a survival factor in dendritic cells. J Immunol (2009) 1.05
LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM. J Leukoc Biol (2005) 1.04
Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J Immunol (2005) 1.04
Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine (2005) 1.04
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect Immun (2005) 1.02
Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol (2005) 0.99
Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation. Proc Natl Acad Sci U S A (2011) 0.99
Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunol Cell Biol (2009) 0.99
4-1BB signaling beyond T cells. Cell Mol Immunol (2011) 0.99
Recombinant glucocorticoid induced tumor necrosis factor receptor (rGITR) induces NOS in murine macrophage. FEBS Lett (2002) 0.99
Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett (2004) 0.98
Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. J Immunol (2005) 0.97
Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Mol Immunol (2007) 0.97
CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent. J Immunol (2007) 0.97
Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology (2006) 0.95
4-1BB costimulation enhances HSV-1-specific CD8+ T cell responses by the induction of CD11c+CD8+ T cells. Cell Immunol (2006) 0.95
Adult stem cells from the hyaluronic acid-rich node and duct system differentiate into neuronal cells and repair brain injury. Stem Cells Dev (2014) 0.93
Characterization of monoclonal antibody specific to the Z39Ig protein, a member of immunoglobulin superfamily. Immunol Lett (2005) 0.93
MCP-1 derived from stromal keratocyte induces corneal infiltration of CD4+ T cells in herpetic stromal keratitis. Mol Cells (2008) 0.92
CD137 is required for M cell functional maturation but not lineage commitment. Am J Pathol (2010) 0.92
Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother (2007) 0.91
The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily. J Biol Chem (2009) 0.91
Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun (2005) 0.90
Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) increased MMP-9 activity in murine macrophage. J Cell Biochem (2003) 0.90
4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells. J Immunol (2011) 0.89
4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J Leukoc Biol (2007) 0.88
Z39Ig is expressed on macrophages and may mediate inflammatory reactions in arthritis and atherosclerosis. J Leukoc Biol (2006) 0.88
Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol (2005) 0.87
Amelioration of mercury-induced autoimmunity by 4-1BB. J Immunol (2006) 0.86
PLP2/A4 interacts with CCR1 and stimulates migration of CCR1-expressing HOS cells. Biochem Biophys Res Commun (2004) 0.86
Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res (2002) 0.86
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther (2009) 0.86
New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells. Trends Immunol (2002) 0.86
Targeting TNF superfamily members for therapeutic intervention in rheumatoid arthritis. Cytokine (2011) 0.85
A novel chemokine, Leukotactin-1, induces chemotaxis, pro-atherogenic cytokines, and tissue factor expression in atherosclerosis. Atherosclerosis (2002) 0.85
Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody. Mol Cells (2007) 0.85
Immunotherapy targeting 4-1BB and its ligand. Int J Hematol (2006) 0.85
CD137 expressed on neutrophils plays dual roles in antibacterial responses against Gram-positive and Gram-negative bacterial infections. Infect Immun (2013) 0.85
Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant. Mol Cells (2011) 0.85
Recombinant glucocorticoid induced tumour necrosis factor receptor (rGITR) induced COX-2 activity in murine macrophage Raw 264.7 cells. Cytokine (2002) 0.85
The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets (2005) 0.84
Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells. Immunology (2006) 0.84
Origins and functional basis of regulatory CD11c+CD8+ T cells. Eur J Immunol (2009) 0.84
Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma. J Immunol (2010) 0.84
Promoter analysis of human CC chemokine CCL23 gene in U937 monocytoid cells. Biochim Biophys Acta (2007) 0.83
TNF superfamily: costimulation and clinical applications. Cell Biol Int (2009) 0.83
A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production. FEBS Lett (2006) 0.83
Characterization and biological activities of humic substances from mumie. J Agric Food Chem (2003) 0.83
Differentiation of CD34+ cells from human cord blood and murine bone marrow is suppressed by C6 beta-chemokines. Mol Cells (2003) 0.83
Herpesvirus infection of ICAM-1-deficient mice. Curr Eye Res (2004) 0.83
Role of peripheral group I and II metabotropic glutamate receptors in IL-1beta-induced mechanical allodynia in the orofacial area of conscious rats. Pain (2005) 0.83
IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo. J Leukoc Biol (2009) 0.83
4-1BB-like molecule is expressed in islet-infiltrating mononuclear cells and in the gray matter of the brain. Cell Biol Int (2002) 0.82
4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy. J Immunother (2014) 0.82
Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice. Immunology (2007) 0.82
CD11c+CD8+ T cells: two-faced adaptive immune regulators. Cell Immunol (2010) 0.82
PDCA expression by B lymphocytes reveals important functional attributes. J Immunol (2009) 0.82